English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17939/22958 (78%)
Visitors : 7386385      Online Users : 142
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24855


    Title: ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
    Authors: Chang, GC;Yang, TY;Chen, KC;Hsu, KH;Huang, YH;Su, KY;Yu, SL;Tseng, JS
    Date: 2020
    Issue Date: 2022-08-09T08:09:05Z (UTC)
    Publisher: NATURE RESEARCH
    ISSN: 2045-2322
    Abstract: It remains unclear how programmed death-ligand 1 ( PD-L1) expression interacts with anaplastic lymphoma kinase (ALK) mutation, its variants, and the outcome of treatment. One hundred and twenty four out of 1255 patients (9.9%) were deemed ALK-positive by the Ventana IHC assay. PD-L1 status and ALK variants were available in 100 and 59 patients, respectively. PD-L1 positive (TPS >= 1%) and strong positive (TPS >= 50%) rate was 50% and 16%, respectively. A total of 64 variant types were detected in 59 patients. V1 ( 32.8%) and V3a/b (28.1%) were the most common variants. There was no significant association between ALK variants and the PD-L1 expression. The presence of V3a/b subtype independently predicted a worse overall survival in patients receiving ALK inhibitor(s) (aHR 5.10 [95% CI 1.22-21.25], P = 0.025) and platinum plus pemetrexed (aHR 9.62 [95% CI 1.90-48.80], P = 0.006). While incorporating ALK variants and PD-L1 expression together, patients with non-V3a/b/positive PD-L1 showed a trend towards longer OS. In conclusion, ALK-positive NSCLC patients possess a high PD-L1 expression rate. Although there was no significant association between PD-L1 expression and ALK variants, the outcome of ALK- positive patients could be sorted by these two biomarkers.
    URI: http://dx.doi.org/10.1038/s41598-020-78152-1
    https://www.webofscience.com/wos/woscc/full-record/WOS:000615394300063
    https://ir.csmu.edu.tw:8080/handle/310902500/24855
    Relation: SCIENTIFIC REPORTS ,2020 ,v10 ,issue 1
    Appears in Collections:[中山醫學大學研究成果] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML265View/Open


    SFX Query

    All items in CSMUIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback